SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Vir Biotechnology Stock Gains on Positive Trial Results for Chronic Hepatitis Treatment

By Kelly CloonanShares of Vir Biotechnology rose after the company reported positive results from two studies for a chronic hepatitis treatment.The stock gained 16% to $14.19 in premarket trading on Monday. At Friday's market close shares had more than doubled year to date.Vir said a Phase 3 trial…

VIR
SquawkNews Desk

Related stories

Microsoft Restores Service After Widespread Outage Microsoft said full service to its products was restored as of early Saturday, including processing undelivered emails. M impact | EQUITY | Nov 14, 2026, 09:57 AM UTC Microsoft Restores Services After Hourslong Global Outage Microsoft said services were fully restored after an hourslong global outage. M impact | EQUITY | Nov 14, 2026, 09:12 AM UTC Rs.4K cr Ramayana movie VFX maker parent Prime Focus shares in focus after 14x profit jump in Q2; stock up 61% in a year New Delhi, Nov. 14 -- Prime Focus Ltd, the parent company of visual effects and animation studio DNEG, is likely to remain in focus on Monday after announcing its September-quarter L impact | EQUITY | Nov 14, 2026, 09:04 AM UTC Microsoft Restores Service After Global Outage Microsoft said its disruption to central cloud services is over. M impact | EQUITY | Nov 14, 2026, 09:01 AM UTC US Flights to Resume After Air Traffic Network Failure US flights are set to resume after an air traffic network failure disrupted operations. M impact | EQUITY | Nov 14, 2026, 08:06 AM UTC UniCredit Raises $3.5 Billion M impact | EQUITY | Nov 14, 2026, 08:03 AM UTC